查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015121

眼科黏弹性手术器材市场：2026-2032年全球市场预测（依产品类型、成分、应用、最终用户及通路划分）

Ophthalmic Viscosurgical Devices Market by Product Type, Composition, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，眼科黏弹性手术器械市场价值将达到 26.6 亿美元，到 2026 年将成长至 28.1 亿美元，到 2032 年将达到 41.8 亿美元，复合年增长率为 6.68%。

主要市场统计数据
基准年 2025 26.6亿美元
预计年份：2026年 28.1亿美元
预测年份 2032 41.8亿美元
复合年增长率 (%) 6.68%

眼科黏弹性手术器械的全面概述：阐述临床意义、不断变化的手术实践挑战以及关键的采购考虑因素。

本执行摘要重点概述了眼科黏弹性手术器械（OVD）及其在现代眼前节和后节手术中的关键作用。内容旨在帮助临床负责人、采购负责人全面了解影响手术中心和医院系统决策的临床因素、产品创新、监管趋势和不断变化的流通结构。

从临床、技术、监管和商业性等多个角度综合观点推动眼科黏弹性手术器材整个价值链快速转型的因素。

近年来，临床、技术和商业性因素的共同作用，促成了多项变革性变化，重塑了光学视觉释放剂（OVD）的市场格局。临床上，微切口白内障手术和高端人工水晶体的日益普及，增加了对能够优化人工水晶体定位、最大限度减少残留并维持前房稳定性的OVD的需求。同时，在外科手术实践中，越来越多的手术转向门诊进行，这增加了对易于操作且即使在高週转率条件下也能保持性能稳定的产品的需求。这些临床进展与产品创新密切相关，配方成分的进步催生了黏弹性自适应和复合成分产品，这些产品在抽吸过程中更易于清除，同时兼具维持眼内空间和保护内皮细胞的双重优势。

对 2025 年美国关税措施将如何造成供应链重组、采购模式变化以及对本地生产投资的奖励进行严格评估。

2025年美国实施的关税措施的累积影响将为製造商、经销商和医疗保健提供者带来一系列新的营运和策略考量。关税带来的成本压力将波及整个供应链，可能增加进口原料和成品口腔黏膜下注射（OVD）产品的成本。按固定还款计画运作且采购预算有限的机构可能面临额外负担，这可能导致与供应商的谈判更加严格，更加重视总体拥有成本，并在可行的情况下转向国内生产替代方案。企业的因应措施不会千篇一律。拥有本地生产能力的大规模综合製造商可以透过规模经济吸收或减轻部分关税影响，而依赖跨境零件采购的小规模供应商则可能面临更严峻的利润率压力。

将产品配方、成分科学、临床应用、最终用户需求和分销管道经济与策略重点连结起来的详细細項分析。

要深入了解细分市场的性能和产品策略，最佳方法是从多个分析观点出发，全面揭示其临床适用性、商业性潜力和操作要求。基于产品类型的分析区分了内聚型、复杂型、可分散型和黏弹性适应型配方。内聚型产品通常优先考虑腔室维护和易于移除，可分散型产品强调在复杂手术过程中对内皮的保护和保留，复杂型配方则平衡了这些特性，而黏弹性适应型溶液则可根据不同的剪切条件调整其特性。基于成分的细分突出了复杂型配方、羟丙基甲基纤维素和透明质酸钠在决定黏弹性行为、使用者偏好和对原材料的依赖性方面的作用。由于其黏弹性稳定性，透明质酸钠仍然是许多先进配方中的首选成分，而羟丙基甲基纤维素则提供了在特定手术流程中至关重要的操作性能。

以区域差异为重点的观点，识别世界各地独特的采购实务、法规要求和供应链考量。

区域趋势影响产品偏好、监管应对措施和供应链设计，从而在关键区域形成不同的竞争格局。在美洲，稳定的手术量、成熟的采购体係以及众多门诊手术中心，催生了对各种OVD製剂的需求，这些製剂优先考虑操作一致性和合规性。在这些市场中运作的製造商必须平衡快速交付和严格品管的期望，并且通常优先考虑产生临床证据和与关键意见领袖（KOL）合作，以促进产品市场渗透。

策略竞争分析重点阐述了创新、供应连续性和附加价值服务如何重新定义OVD产业的领导地位和差异化优势。

口腔病毒分泌物（OVD）领域的竞争格局呈现出传统製造商、专业製造商和新兴企业采用差异化的打入市场策略。主要企业正加大对配方科学的投入，以拓展临床效用，同时也致力于改进包装和给药系统，从而提高操作便利性并减少废弃物。其策略重点包括加强与临床机构的直接合作，确保高纯度透明质酸原料的稳定供应，以及利用监管部门的核准，拓展关键治疗应用领域的适应症。

一份切实可行的策略蓝图，建议投资于配方研发、供应来源多元化、经营模式调整以及监管合规准备，以维持成长。

产业领导企业应考虑采取多管齐下的策略，涵盖临床差异化、供应链韧性、商业性灵活性和监管前瞻性。首先，他们应优先投资于配方科学，旨在透过改善内皮保护、提高移除便利性或优化黏弹性行为，实现显着的临床优势，从而打造外科医生能够轻鬆融入标准工作流程的强大产品差异化优势。其次，他们应透过策略性合约和供应商多角化来加强原物料采购体系，从而减轻贸易中断的影响，并提升自身在成本和前置作业时间上的议价能力。

透明严谨的研究途径，结合专家访谈、监管审查、临床文献整合和迭代检验，确保获得可操作的见解。

本摘要的研究采用了结构化一手访谈、有针对性的二手资料分析和系统性检验验证相结合的方法，以确保研究结果的稳健性和相关性。一手资料是透过对眼科医生、门诊和医院采购负责人、监管专家以及高级销售主管的详细访谈收集的，相关人员从各自的角度提供了关于临床重点、采购决定因素和供应链挑战的背景观点。二手资料包括公开的监管文件、临床文献、医疗设备註册数据和企业披露信息，这些信息被整合起来以检验临床声明、生产实践和分销模式。

一份简明扼要、综合全面的分析报告，重点关注临床因素、供应弹性以及为应对眼科医疗设备不断变化的趋势而必须采取的客製化商业策略。

总之，眼科黏弹剂（OVD）领域具有持续的临床意义、加速的创新以及适应新的手术流程和采购现实的商业性环境等特征。临床需求仍然是主要驱动力。能够可靠保护眼组织、支援先进的眼内手术并能无缝整合到高通量环境中的製剂将吸引临床医生和采购相关人员的注意。同时，供应链的韧性和监管的灵活性正成为至关重要的营运重点，尤其是在贸易政策不断变化和原材料供应波动的情况下。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：眼科黏弹性手术器材市场：依产品类型划分

  • 凝聚力
  • 复杂类型
  • 去中心化
  • 黏弹性自适应型

第九章 眼科黏弹性手术器材市场：依组件划分

  • 组合
  • 羟丙基甲基纤维素
  • 透明质酸钠

第十章：眼科黏弹性手术器械市场：依应用领域划分

  • 白内障手术
  • 角膜手术
  • 青光眼手术
  • 玻璃体视网膜手术

第十一章：眼科黏弹性手术器械市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章：眼科黏弹性手术器械市场：依分销管道划分

  • 直销
  • 销售代理

第十三章：眼科黏弹性手术器材市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：眼科黏弹性手术器材市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：眼科黏弹性手术器械市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国眼科黏弹性手术器械市场

第十七章：中国黏弹性眼科手术器材市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alcon Inc.
  • Altacor Limited
  • Amring Pharmaceuticals Inc.
  • Bausch+Lomb Incorporated
  • Beaver-Visitec International, Inc.
  • Bohus BioTech AB
  • Carl Zeiss Meditec AG
  • CIMA Technology, Inc.
  • HOYA Corporation
  • Johnson & Johnson Vision Care, Inc.
  • Precision Lens Co. Ltd.
  • Rayner Intraocular Lenses Limited
  • Rumex International Corporation
  • Santen Pharmaceutical Co., Ltd.
  • Shanghai Haohai Biological Technology Co., Ltd.
Product Code: MRR-036C5CF3B495

The Ophthalmic Viscosurgical Devices Market was valued at USD 2.66 billion in 2025 and is projected to grow to USD 2.81 billion in 2026, with a CAGR of 6.68%, reaching USD 4.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.66 billion
Estimated Year [2026] USD 2.81 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 6.68%

A comprehensive orientation to ophthalmic viscosurgical devices outlining clinical importance, evolving surgical practice pressures, and procurement imperatives

This executive summary provides a focused orientation to ophthalmic viscosurgical devices (OVDs) and their pivotal role in contemporary anterior and posterior segment surgery. The content is designed to equip clinical leaders, procurement executives, and product strategists with a balanced synthesis of clinical drivers, product innovation, regulatory dynamics, and distribution shift factors that collectively shape decision-making across surgical centers and hospital systems.

OVDs serve as indispensable adjuncts during cataract, corneal, glaucoma, and vitreoretinal procedures, protecting ocular tissues while enabling visualization and access. As surgical techniques continue to evolve toward smaller incisions and faster throughput, the expectations placed on OVD performance, handling characteristics, and supply reliability have intensified. This introduction outlines the framing assumptions used across subsequent sections, emphasizing clinical utility, supplier behavior, regulatory influences, and end-user procurement priorities. It sets the stage for deeper insights into transformative trends, tariff impacts, segmentation nuances, regional differentiation, and strategic actions that industry stakeholders should consider.

An integrated view of the clinical, technological, regulatory, and commercial forces driving rapid transformation across the ophthalmic viscosurgical devices value chain

Several transformative shifts have reshaped the OVD landscape in recent years, driven by converging clinical, technological, and commercial forces. Clinically, the widespread adoption of microincision cataract surgery and premium intraocular lenses has increased demand for OVDs that provide sustained anterior chamber stability while minimizing residue and optimizing intraocular lens positioning. Concurrently, surgical practice has migrated more procedures to ambulatory settings, creating a premium on products that combine ease of handling with consistent performance under high-turnover conditions. These clinical evolutions are tightly coupled with product innovation, where formulary advances are producing viscoadaptive and combination compositions intended to deliver dual benefits of space maintenance and endothelial protection, while enabling simplified removal during aspiration.

On the regulatory and quality front, heightened scrutiny over sterility assurance, supply chain traceability, and device classification has prompted manufacturers to invest in enhanced quality systems and in some cases to redesign packaging and labeling to align with new regional requirements. The supply chain itself is undergoing consolidation; strategic partnerships and selective vertical integration are being used to stabilize raw material sourcing-particularly for high-purity sodium hyaluronate-and to improve manufacturing resilience. Digital channels and direct-to-provider distribution models continue to expand, altering traditional distributor relationships and enabling more granular data capture on usage patterns. Taken together, these shifts are accelerating portfolio rationalization, encouraging investments in differentiated formulations and delivery systems, and elevating the importance of cross-functional collaboration between clinical, regulatory, and commercial teams.

A rigorous assessment of how 2025 tariff measures in the United States create supply chain recalibration, procurement shifts, and incentives for localized manufacturing investments

The cumulative effects of tariff measures implemented in the United States during 2025 introduce a new set of operational and strategic considerations for manufacturers, distributors, and healthcare providers. Tariff-induced cost pressures are likely to be transmitted through the supply chain, increasing landed costs for imported raw materials and finished OVD products. Facilities operating under fixed reimbursement schedules and constrained procurement budgets may experience added strain, prompting more rigorous supplier negotiations, greater emphasis on total cost of ownership, and potential shifts toward domestically produced alternatives where feasible. The operational response is not uniform; larger integrated manufacturers with localized production capabilities can absorb or mitigate some tariff impacts through scale, while smaller suppliers that rely on cross-border component sourcing may face more acute margin compression.

Procurement strategies at hospitals and ambulatory centers tend to adjust via longer contract cycles, expanded use of framework agreements that lock in prices, or heightened reliance on group purchasing organizations that aggregate demand to secure more favorable terms. In parallel, distributors may reconfigure inventory strategies to hedge against tariff volatility and to preserve service levels, increasing safety stock or rebalancing geographic inventory pools. On the innovation side, tariff pressure creates an incentive to optimize formulations for cost-effective raw material use and to redesign packaging to reduce import duty classifications where legally permissible. Over the medium term, policy-driven trade barriers can accelerate regional manufacturing investments and supplier diversification as companies seek to protect margin and maintain supply reliability for high-volume surgical settings. In sum, tariffs act as a catalyst for supply chain reconfiguration, procurement optimization, and selective onshoring where economic and regulatory conditions justify capital investment.

In-depth segmentation analysis that connects product formulation, composition science, clinical application, end-user requirements, and distribution channel economics to strategic priorities

Segment-level performance and product strategy are best understood through multiple analytical lenses that together reveal clinical fit, commercial potential, and operational requirements. Analysis by product type differentiates Cohesive, Combined, Dispersive, and Viscoadaptive formulations, where cohesive products typically prioritize chamber maintenance and facile removal, dispersive variants emphasize endothelial protection and retention during complex maneuvers, combined formulations seek to balance those attributes, and viscoadaptive solutions adapt properties under changing shear conditions. Composition-based segmentation highlights the role of Combination products, Hydroxypropyl Methylcellulose, and Sodium Hyaluronate in determining viscoelastic behavior, user preference, and raw material dependencies; sodium hyaluronate continues to be favored in many advanced formulations for its viscoelastic stability, while hydroxypropyl methylcellulose offers handling profiles valued in specific surgical workflows.

Application-based distinctions across Cataract Surgery, Corneal Surgery, Glaucoma Surgery, and Vitreoretinal Surgery illuminate divergent clinical requirements. Cataract procedures demand OVDs that enable predictable capsular support and lens placement, corneal interventions prioritize endothelial protection, glaucoma surgeries emphasize space maintenance for angle-based maneuvers, and vitreoretinal operations often require specialized handling during posterior segment access. End-user segmentation covering Ambulatory Surgery Centers, Hospitals, and Specialty Clinics underscores procurement and usage differences; ambulatory centers value products that support throughput and ease of use, hospitals often require a broader formulary to accommodate complex cases, and specialty clinics may demand niche formulations aligned to subspecialty procedures. Distribution channel analysis across Direct Sales, Distributor Partners, and Ecommerce reveals contrasting go-to-market models: direct sales can deliver tailored clinical support and contracting, distributor partners facilitate broad geographic reach and inventory management, and ecommerce channels provide convenience and data transparency but require robust logistics and regulatory compliance mechanisms. Combined, these segmentation perspectives inform product development priorities, clinical education programs, and commercial channel investments that align with specific procedural and customer needs.

A regionally nuanced perspective identifying distinct procurement behaviors, regulatory imperatives, and supply chain considerations across global territories

Regional dynamics shape product preferences, regulatory pathways, and supply chain design, producing differentiated competitive landscapes across major territories. In the Americas, established surgical volumes, mature procurement systems, and a strong presence of ambulatory surgery centers create demand for a wide range of OVD formulations that emphasize handling consistency and regulatory compliance. Manufacturers operating in these markets must balance rapid service expectations with stringent quality oversight, and they often prioritize clinical evidence generation and KOL engagement to support product adoption.

Europe, Middle East & Africa present a heterogeneous environment where divergent reimbursement frameworks, variable regulatory harmonization, and regional supply chain complexities necessitate localized market approaches. In some countries within this region, centralized procurement or hospital group purchasing drives price sensitivity, while in others, clinical preference and specialist networks exert stronger influence on adoption. Manufacturers benefit from adaptable regulatory strategies and targeted clinical programs to navigate this diversity. Asia-Pacific displays a combination of high-volume demand centers, rapid surgical capacity expansion, and growing domestic manufacturing capabilities. The region includes fast-growing ambulatory networks alongside large tertiary hospitals, and stakeholders often prioritize cost-effective formulations paired with robust supply continuity. Across all regions, cross-border regulatory alignment, export controls, and raw material sourcing considerations play pivotal roles in shaping manufacturing footprints and distribution strategies.

Strategic competitive analysis highlighting how innovation, supply continuity, and value-added services are redefining leadership and differentiation in the OVD sector

Competitive dynamics within the OVD space are characterized by a mix of legacy manufacturers, specialists, and emerging players employing differentiated go-to-market strategies. Leading firms are investing in formulation science to extend clinical utility while also refining packaging and delivery systems to improve handling and reduce waste. Strategic priorities include expanding direct clinical engagement, securing raw material supply chains for high-purity hyaluronate sources, and leveraging regulatory approvals to support label expansions in key therapeutic applications.

Smaller and mid-sized companies often focus on niche indications, cost-competitive formulations, or geographically targeted distribution partnerships to consolidate presence. Across tiers, companies are increasingly pursuing collaborative models that combine clinical training programs with bundled procurement offers for ambulatory centers and hospital systems. Mergers and acquisitions remain an active strategic lever, used to acquire proprietary formulations, expand manufacturing capacity, or access complementary distribution networks. Service differentiation through clinical education, post-market surveillance, and value-based contracting is becoming more central to competitive positioning as buyers expect not only product performance but also predictable supply and demonstrable outcomes support. Intellectual property management and quality system maturity continue to be critical determinants of competitive advantage, particularly for companies seeking to expand into regulated markets with rigorous approval requirements.

Actionable strategic roadmap recommending formulation investment, supply diversification, commercial model adaptation, and regulatory preparedness to sustain growth

Industry leaders should consider a multi-pronged approach that addresses clinical differentiation, supply resilience, commercial agility, and regulatory foresight. First, prioritize investment in formulation science that targets clear clinical advantages-whether through improved endothelial protection, ease of removal, or optimized viscoelastic behavior-to create defensible product differentiation that surgeons can readily adopt within standard workflows. Next, strengthen raw material sourcing through strategic agreements and diversified supplier bases to reduce exposure to trade disruptions and to improve negotiating leverage on cost and lead times.

Commercial models should be adapted to evolving procurement landscapes by expanding direct engagement with ambulatory surgery centers and large hospital systems, while refining distributor relationships to ensure geographic coverage and inventory responsiveness. Digital enablement across ordering, inventory visibility, and post-market feedback can enhance customer experience and provide actionable usage data. Regulatory and quality systems must be continuously upgraded to address emerging regional requirements and to accelerate label expansions; proactive engagement with regulatory authorities and investment in robust clinical evidence will facilitate market access. Finally, develop contingency plans for tariff and trade policy volatility that combine flexible inventory strategies, regional production options, and cost engineering to protect margins without compromising clinical performance. These recommendations together form an actionable roadmap to drive adoption, protect supply, and sustain competitive momentum.

A transparent and rigorous research approach combining expert interviews, regulatory review, clinical literature synthesis, and iterative triangulation to ensure actionable findings

The research underpinning this summary relied on a blend of structured primary interviews, targeted secondary analysis, and methodical triangulation to ensure robustness and relevance. Primary inputs were gathered through in-depth interviews with ophthalmic surgeons, procurement officers from ambulatory and hospital settings, regulatory experts, and senior commercial executives, all of whom provided contextual perspectives on clinical priorities, purchasing drivers, and supply chain challenges. Secondary inputs included publicly available regulatory documents, clinical literature, device registries, and corporate disclosures, which were synthesized to validate clinical claims, manufacturing practices, and distribution models.

Data and insight triangulation was applied to reconcile discrepancies between stakeholder perspectives and published information, with iterative validation cycles used to refine interpretations. The methodology incorporated careful attention to regional regulatory frameworks and to procedural trends that influence formulation selection and usage patterns. Where assumptions were required, they were explicitly tested through follow-up interviews and scenario analysis to assess sensitivity to policy shifts, procurement changes, and clinical adoption barriers. The overall approach emphasizes transparency in source provenance, disciplined cross-validation, and the integration of clinical and commercial viewpoints to produce actionable intelligence for decision-makers.

A concise synthesis emphasizing clinical drivers, supply resilience, and coordinated commercial strategies necessary to navigate evolving ophthalmic device dynamics

In closing, the OVD segment is marked by enduring clinical relevance, accelerating innovation, and a commercial landscape that is adapting to new surgical workflows and procurement realities. Clinical needs remain the primary driver: formulations that reliably protect ocular tissues, support advanced intraocular procedures, and integrate smoothly into high-throughput settings will command attention from clinicians and purchasing stakeholders alike. At the same time, supply chain resilience and regulatory agility have emerged as essential operational priorities, particularly in the context of trade policy shifts and fluctuating raw material access.

Stakeholders who align product development with clear procedural benefits, who invest in demonstrable clinical evidence, and who pursue flexible commercial models will be best positioned to capture long-term value. The interplay between formulation innovation, regional regulatory differences, and distribution model evolution underscores the need for coordinated strategies that span R&D, manufacturing, and customer engagement. By focusing on clinical differentiation, supply continuity, and responsive commercial execution, industry participants can navigate near-term disruptions while building durable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ophthalmic Viscosurgical Devices Market, by Product Type

  • 8.1. Cohesive
  • 8.2. Combined
  • 8.3. Dispersive
  • 8.4. Viscoadaptive

9. Ophthalmic Viscosurgical Devices Market, by Composition

  • 9.1. Combination
  • 9.2. Hydroxypropyl Methylcellulose
  • 9.3. Sodium Hyaluronate

10. Ophthalmic Viscosurgical Devices Market, by Application

  • 10.1. Cataract Surgery
  • 10.2. Corneal Surgery
  • 10.3. Glaucoma Surgery
  • 10.4. Vitreoretinal Surgery

11. Ophthalmic Viscosurgical Devices Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Ophthalmic Viscosurgical Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributor Partners

13. Ophthalmic Viscosurgical Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ophthalmic Viscosurgical Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ophthalmic Viscosurgical Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ophthalmic Viscosurgical Devices Market

17. China Ophthalmic Viscosurgical Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alcon Inc.
  • 18.6. Altacor Limited
  • 18.7. Amring Pharmaceuticals Inc.
  • 18.8. Bausch + Lomb Incorporated
  • 18.9. Beaver-Visitec International, Inc.
  • 18.10. Bohus BioTech AB
  • 18.11. Carl Zeiss Meditec AG
  • 18.12. CIMA Technology, Inc.
  • 18.13. HOYA Corporation
  • 18.14. Johnson & Johnson Vision Care, Inc.
  • 18.15. Precision Lens Co. Ltd.
  • 18.16. Rayner Intraocular Lenses Limited
  • 18.17. Rumex International Corporation
  • 18.18. Santen Pharmaceutical Co., Ltd.
  • 18.19. Shanghai Haohai Biological Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)